Jump to content

HRS9531

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by JoeNMLC (talk | contribs) at 18:37, 4 December 2023 (→top: ce, rm orphan tag (Query 38614); ► Wikiproject Orphanage: You can help! ●). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

HRS9531 is an experimental GLP-1 and GIPR dual agonist developed by Jiangsu Hengrui.[1][2][3]

References

  1. ^ Goldenberg, Ronald M.; Gilbert, Jeremy D.; Manjoo, Priya; Pedersen, Sue D.; Woo, Vincent C.; Lovshin, Julie A. (15 November 2023). "Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists". Obesity Reviews. doi:10.1111/obr.13663.
  2. ^ Goldenberg, Ronald M.; Teoh, Hwee; Verma, Subodh (November 2023). "Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data". Current Opinion in Cardiology. 38 (6): 539–545. doi:10.1097/HCO.0000000000001084.
  3. ^ He, Kun; Wei, Fang; Chen, Hong; Zhang, Yanyan; Sheng, Zhen; Wen, Qing (20 June 2023). "763-P: Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of a Dual GLP-1/GIP Receptor Agonist (HRS9531) in Healthy Subjects—A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose (SAD and MAD) Study". Diabetes. 72 (Supplement_1). doi:10.2337/db23-763-P.
Retrieved from "https://en.wikipedia.org/w/index.php?title=HRS9531&oldid=1188328878"